Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02142 和鉑醫藥控股
HBM Holdings
Listing Date2020/12/10
Listing Price12.380
  • 8.800 -0.390 (-4.244%)    Sink Below Listing Price
  • 15-min delayed, last update: 02/12/2021 16:57
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    20 lot
  • One Lot Success Rate

HBM Holdings incorporated in July 2016, it is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It had a diversified and balanced pipeline of more than ten potentially differentiated drug candidates, among which its Core Product batoclimab, tanfanercept and HBM4003 are in clinical development stage. Batoclimab and tanfanercept were in-licensed from HanAll and were not generated from its Harbour antibody platforms.

Since the in-licensing of batoclimab, the Group has independently completed the Phase 1 clinical trial in Hong Kong; initiated the registrational Phase 2/3 clinical trial in ITP in Greater China in March 2020; initiated the Phase 2 clinical trial in MG in Greater China in March 2020 and initiated the Phase 1b/2 clinical trial in NMOSD in Greater China in January 2020. In addition, the ongoing trials in ITP, MG and NMOSD have dosed the first patient.

Since the in-licensing of tanfanercept, the Group has completed the Phase 2 clinical trial in Greater China and initiated the registrational Phase 3 clinical trial in Greater China in August 2020.

The Group Harbour antibody platforms – HCAb Platform, HBICETM Platform and H2L2 Platform – constitute what it believes to be a comprehensive technology solution1 available for discovering the next generation of fully human antibody therapeutics. Its Harbour antibody platforms have been validated by over 45 industry and academic partners with six projects having entered clinical stage as of 30 June 2020.

MarketHong Kong (Main Board)
Business NatureHealth Care
Board Lot1,000
Registrar & Transfer OfficeTricor Investor Services
No. of Offer Shares138m shares
No. of International Offer Shares124m shares
No. of HK Offer Shares13.82m shares
Offer Price$11.70 - $12.92
Nominal ValueUS$ 0.000025 each
Stock Code2142
Joint SponsorsMorgan Stanley Asia, Merrill Lynch Far East, CLSA Capital Markets
Joint Global CoordinatorsMorgan Stanley Asia, Merrill Lynch (Asia Pacific), CLSA, China International Capital Corporation Hong Kong Securities, Credit Suisse (Hong Kong)
Joint BookrunnersMorgan Stanley Asia, Morgan Stanley & Co. International, Merrill Lynch (Asia Pacific), CLSA, China International Capital Corporation Hong Kong Securities, Credit Suisse (Hong Kong), Haitong International Securities, BOCI Asia
Joint Lead ManagersMorgan Stanley Asia, Morgan Stanley & Co. International, Merrill Lynch (Asia Pacific), CLSA, China International Capital Corporation Hong Kong Securities, Credit Suisse (Hong Kong)
Application PeriodNov 30 (Mon) - Noon, Dec 3 (Thu)
Price Determination DateOn or Before 5pm, Dec 3 (Thu)
Result Announcement DateOn or Before Dec 9 (Wed)
Dispatch of Shares and Refund ChequesOn or Before Dec 9 (Wed)
Dealings in Shares commence onDec 10, 2020. (Thu)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
ExecutiveJingsong Wang (Chairman), Mai-Jing Liao, Atul Mukund Deshpande
Non-ExecutiveYu Min Qiu, Junfeng Wang
Independent Non-ExecutiveRobert Irwin Kamen, Xiaoping Ye, Weiwei Chen
Golden Link Investment12.18%
Legend Capital8.53%
Director Jingsong Wang7.86%
GIC Private6.59%
(Year ended Dec 31)
2020 *20192018
Gross Profit5,7834,796836
Pre-Taxed Profit(48,436)(67,588)(34,639)
Attributable Profit for the period(48,305)(67,460)(34,583)
* For the six months ended June 30, 2020.
Offer Price$11.70 - $12.92
Capitalization$8,984m - $9,921m
Unaudited pro forma adj NAV / share$3.00 - $3.21
Assuming the offer price being at the mid-point of $12.31, the net proceeds raised would be HK$1,589.5m, of which:
* $588.1m (37.0%) to fund Core Products, including batoclimab (HBM9161) and tanfanercept (HBM9036), and specifically;
* $365.6m (23.0%) to be used to fund ongoing and planned clinical trials in Greater China and Australia, preparation for registration filings and potential commercial launches of HBM4003;
* $238.4m (15.0%) to fund the research and development of other drug candidates seeking IND approvals and yet to commence clinical trials or those in pre-clinical studies;
* $190.7m (12.0%) to fund the discovery of innovative molecules generated from Harbour antibody platforms;
* $79.5m (5.0%) to fund the continued improvement of platform technologies and pursuit of licensing and collaboration opportunities utilizing our Harbour antibody platforms ;
* the balance of $127.2m (8.0%) as additional working capital.
Code Name Nominal Change %Change
01801INNOVENT BIOdown67.400-0.800-1.173%
01877JUNSHI BIOdown44.550-0.450-1.000%
01952EVEREST MED-Bdown33.400-0.600-1.765%
02142HBM HOLDINGS-Bdown8.800-0.390-4.244%
02552HUA MEDICINE-Bup4.1200.0902.233%
02616CSTONE PHARMA-Bdown9.870-0.290-2.854%
03681SINOMAB BIO-Bunchange2.9000.0000.000%
15-min delayed, last updated: 02/12/2021 16:57
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.